High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model
Stem Cell Reviews and Reports · 2017-06 · 13 (3) · 335-346
DOI: 10.1007/s12015-017-9736-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Stem Cell Reviews and Reports, online erschienen am 20.04.2017. Verfasst von Genevieve Conant und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Drug Evaluation, Preclinical, Lab-On-A-Chip Devices, Models, Cardiovascular. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 116 Literaturangaben. Gefördert von: CIHR, Natural Sciences and Engineering Research Council of Canada, Ontario Council on Graduate Studies, Council of Ontario Universities.
Abstract (Originalsprache)
Drug discovery and development continues to be a challenge to the pharmaceutical industry despite great advances in cell and molecular biology that allow for the design of better targeted therapeutics. Many potential drug compounds fail during the clinical trial due to inefficacy and toxicity that were not predicted during preclinical stages. The fundamental problem lies with the use of traditional drug screening models that still largely rely on the use of cell lines or animal cell monolayers, which leads to lack of predictive power of human tissue and organ response to the drug candidates. More physiologically relevant systems are therefore critical in relieving the burden of high failure rates. Emerging knowledge and techniques in tissue engineering and microfabrication have enabled the development of micro-engineered systems - collectively known as organs-on-chips - that may lead to a paradigm shift in preclinical drug screening assays. In this review we explore the technological advances and challenges in the development of heart-on-a-chip models, by addressing current assessment methods for drug-induced cardiotoxicity and providing a perspective on the modifications that should be implemented to realize the full potential of this system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada.
- Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, ON, Canada.
- Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada. m.radisic@utoronto.ca.
- Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, ON, Canada. m.radisic@utoronto.ca.
- Toronto General Research Institute, Toronto, ON, Canada. m.radisic@utoronto.ca.
Förderung
- CIHR
- Natural Sciences and Engineering Research Council of Canada
- Ontario Council on Graduate Studies, Council of Ontario Universities
- Canadian Institutes of Health Research
Zitieren
APA
Conant, G., Lai, B. F. L., Lu, R. X. Z., Korolj, A., Wang, E. Y., & Radisic, M. (2017). High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model. Stem Cell Reviews and Reports, 13(3), 335-346. https://doi.org/10.1007/s12015-017-9736-2
Vancouver
Conant G, Lai BFL, Lu RXZ, Korolj A, Wang EY, Radisic M. High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model. Stem Cell Reviews and Reports. 2017;13(3):335-346. doi:10.1007/s12015-017-9736-2
BibTeX
@article{Conant2017,
author = {Conant, Genevieve and Lai, Benjamin Fook Lun and Lu, Rick Xing Ze and Korolj, Anastasia and Wang, Erika Yan and Radisic, Milica},
title = {High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model},
journal = {Stem Cell Reviews and Reports},
year = {2017},
volume = {13},
number = {3},
pages = {335--346},
doi = {10.1007/s12015-017-9736-2}
}
EUVIMED